Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA in Subjects With Solid Tumors

NCT04013217 is registered in ClinicalTrials.gov with Health Hope Pharma as lead sponsor.

NCT NCT04013217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04013217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Eribulin ORA in Subjects With Solid Tumors
Lead sponsor
Health Hope Pharma
Phase
Phase 1
Overall status
Terminated
Start date
July 29, 2019
Completion date
March 2, 2022
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor